TN2015000029A1 - Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors - Google Patents
Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitorsInfo
- Publication number
- TN2015000029A1 TN2015000029A1 TNP2015000029A TN2015000029A TN2015000029A1 TN 2015000029 A1 TN2015000029 A1 TN 2015000029A1 TN P2015000029 A TNP2015000029 A TN P2015000029A TN 2015000029 A TN2015000029 A TN 2015000029A TN 2015000029 A1 TN2015000029 A1 TN 2015000029A1
- Authority
- TN
- Tunisia
- Prior art keywords
- bruton
- btk
- inhibitors
- arthritis
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261681684P | 2012-08-10 | 2012-08-10 | |
PCT/US2013/054096 WO2014025976A1 (fr) | 2012-08-10 | 2013-08-08 | Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk) |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2015000029A1 true TN2015000029A1 (en) | 2016-06-29 |
Family
ID=49029216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2015000029A TN2015000029A1 (en) | 2012-08-10 | 2015-01-19 | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
Country Status (25)
Country | Link |
---|---|
US (5) | US20140045813A1 (fr) |
EP (1) | EP2882741B1 (fr) |
JP (1) | JP6348492B2 (fr) |
KR (1) | KR20150040292A (fr) |
CN (1) | CN104603124B (fr) |
AP (1) | AP2015008203A0 (fr) |
AU (1) | AU2013299557B2 (fr) |
BR (1) | BR112015002590A2 (fr) |
CA (1) | CA2881519A1 (fr) |
CL (1) | CL2015000256A1 (fr) |
EA (1) | EA029210B1 (fr) |
EC (1) | ECSP15008851A (fr) |
GE (1) | GEP201706748B (fr) |
HK (1) | HK1210161A1 (fr) |
IL (1) | IL236495A0 (fr) |
IN (1) | IN2015DN00524A (fr) |
MA (1) | MA37830B1 (fr) |
MX (1) | MX2015001802A (fr) |
NZ (1) | NZ703607A (fr) |
PE (1) | PE20150756A1 (fr) |
PH (1) | PH12015500294A1 (fr) |
SA (1) | SA515360007B1 (fr) |
SG (1) | SG11201500499TA (fr) |
TN (1) | TN2015000029A1 (fr) |
WO (1) | WO2014025976A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015002590A2 (pt) | 2012-08-10 | 2019-08-06 | Boehringer Ingelheim Int | compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk) |
JP6178861B2 (ja) * | 2012-11-02 | 2017-08-09 | ファイザー・インク | ブルトン型チロシンキナーゼ阻害剤 |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
EP2970163B1 (fr) * | 2013-03-14 | 2018-02-28 | Boehringer Ingelheim International GmbH | Dérivés de 5-thiazolecarboxamide et leur utilisation en tant qu'inhibiteurs de la btk |
DK2970291T3 (da) * | 2013-03-15 | 2022-08-01 | Janssen Pharmaceutica Nv | Fremgangsmåder og mellemprodukter til fremstilling af et medikament |
EP2970300B1 (fr) | 2013-03-15 | 2018-05-16 | Boehringer Ingelheim International GmbH | Composés hétéroaromatiques en tant qu'inhibiteurs btk |
SI3052476T1 (sl) * | 2013-09-30 | 2020-12-31 | Guangzhou Innocare Pharma Tech Co., Ltd. | Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
US9828364B2 (en) * | 2014-01-29 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as BTK inhibitors |
WO2015185998A2 (fr) * | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
CN105884747B (zh) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法 |
LT3390395T (lt) * | 2015-12-16 | 2020-11-25 | Loxo Oncology, Inc. | Junginiai, naudingi kaip kinazės inhibitoriai |
EA034561B1 (ru) * | 2015-12-16 | 2020-02-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний |
CN105646318A (zh) * | 2015-12-30 | 2016-06-08 | 武汉药明康德新药开发有限公司 | 一种2-叔丁氧羰基-5-氮杂螺环[3.3]庚烷-6-羧酸的合成方法 |
US10570118B2 (en) | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
CN107226805A (zh) * | 2016-03-24 | 2017-10-03 | 北京天诚医药科技有限公司 | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 |
CN109641965A (zh) * | 2016-08-15 | 2019-04-16 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
CN107759602B (zh) * | 2016-08-17 | 2020-04-21 | 中国科学院上海药物研究所 | 含有共轭联烯结构的化合物、其药物组合物和用途 |
JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
JP7166331B2 (ja) * | 2017-08-01 | 2022-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 中間体化合物及び方法 |
TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020120673A1 (fr) * | 2018-12-13 | 2020-06-18 | Intervet International B.V. | Procédé de préparation de 1-[(3r,4s)-4-cyanotétrahydropyran-3-yl]-3-[(2-fluoro-6-méthoxy-4-pyridyl)amino]pyrazole-4-carboxamide |
KR102200032B1 (ko) * | 2019-03-13 | 2021-01-08 | 전남대학교산학협력단 | 호흡기 질환의 예방 또는 치료용 조성물 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
CN114573586B (zh) * | 2020-11-28 | 2023-11-03 | 杭州和正医药有限公司 | 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用 |
WO2023110936A1 (fr) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Inhibiteurs de kinase réversibles macrocycliques |
WO2023110970A1 (fr) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Inhibiteurs macrocycliques de btk |
WO2024028458A2 (fr) * | 2022-08-04 | 2024-02-08 | Heptares Therapeutics Limited | Agonistes du récepteur muscarinique |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
DE60211348T2 (de) * | 2001-08-13 | 2007-02-08 | Janssen Pharmaceutica N.V. | 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung |
WO2003072541A2 (fr) | 2001-09-27 | 2003-09-04 | Smithkline Beecham Corporation | Composes chimiques |
FR2881426B1 (fr) * | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
WO2007117692A2 (fr) * | 2006-04-11 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, et pyrazoles utiles en tant qu'inhibiteurs de protéines kinases |
AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
EP2081435B1 (fr) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
EP2560007A1 (fr) * | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification des Inhibiteurs de la tyrosine kinase de bruton |
CA2728016C (fr) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Nouvelles pyridine-2-ones et pyridazine-3-ones substituees |
ES2445099T3 (es) | 2008-07-29 | 2014-02-28 | Université de Liège | Una prueba de marcador genético para braquispina y fertilidad en ganado vacuno |
GB0820819D0 (en) * | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
CA2750935A1 (fr) * | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryles et applications associees |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
JP2013514287A (ja) | 2009-12-17 | 2013-04-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | スフィンゴシンキナーゼの阻害薬 |
MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
EP2603216A4 (fr) * | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Hétéroaryles et utilisations |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
CA2834077A1 (fr) | 2011-05-17 | 2012-11-22 | F. Hoffmann-La Roche Ag | Inhibiteurs de tyrosine kinase de bruton |
BR112014003582A2 (pt) | 2011-08-17 | 2017-03-14 | Hoffmann La Roche | inibidores da tirosina quinase de bruton |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
EP2809673B1 (fr) | 2012-01-31 | 2016-11-02 | Nanjing Allgen Pharma Co. Ltd. | Molécules spirocycliques en tant qu'inhibiteurs de tyrosine kinase de bruton |
JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
BR112015002590A2 (pt) | 2012-08-10 | 2019-08-06 | Boehringer Ingelheim Int | compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk) |
JP2015531781A (ja) | 2012-09-13 | 2015-11-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトン型チロシンキナーゼの阻害剤 |
JP6178861B2 (ja) | 2012-11-02 | 2017-08-09 | ファイザー・インク | ブルトン型チロシンキナーゼ阻害剤 |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
EP2970300B1 (fr) | 2013-03-15 | 2018-05-16 | Boehringer Ingelheim International GmbH | Composés hétéroaromatiques en tant qu'inhibiteurs btk |
CN105745202A (zh) | 2013-09-03 | 2016-07-06 | 卡尔那生物科学株式会社 | 新型2,6-二氨基嘧啶衍生物 |
US9828364B2 (en) | 2014-01-29 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as BTK inhibitors |
EA034561B1 (ru) | 2015-12-16 | 2020-02-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний |
-
2013
- 2013-08-08 BR BR112015002590A patent/BR112015002590A2/pt not_active Application Discontinuation
- 2013-08-08 CN CN201380041869.4A patent/CN104603124B/zh not_active Expired - Fee Related
- 2013-08-08 NZ NZ703607A patent/NZ703607A/en not_active IP Right Cessation
- 2013-08-08 SG SG11201500499TA patent/SG11201500499TA/en unknown
- 2013-08-08 WO PCT/US2013/054096 patent/WO2014025976A1/fr active Application Filing
- 2013-08-08 MA MA37830A patent/MA37830B1/fr unknown
- 2013-08-08 IN IN524DEN2015 patent/IN2015DN00524A/en unknown
- 2013-08-08 US US13/962,260 patent/US20140045813A1/en not_active Abandoned
- 2013-08-08 KR KR20157003386A patent/KR20150040292A/ko active Search and Examination
- 2013-08-08 CA CA2881519A patent/CA2881519A1/fr not_active Abandoned
- 2013-08-08 PE PE2015000173A patent/PE20150756A1/es not_active Application Discontinuation
- 2013-08-08 MX MX2015001802A patent/MX2015001802A/es unknown
- 2013-08-08 JP JP2015526696A patent/JP6348492B2/ja active Active
- 2013-08-08 AP AP2015008203A patent/AP2015008203A0/xx unknown
- 2013-08-08 GE GEAP201313757A patent/GEP201706748B/en unknown
- 2013-08-08 EP EP13752756.0A patent/EP2882741B1/fr active Active
- 2013-08-08 EA EA201500207A patent/EA029210B1/ru not_active IP Right Cessation
- 2013-08-08 AU AU2013299557A patent/AU2013299557B2/en not_active Ceased
-
2014
- 2014-12-28 IL IL236495A patent/IL236495A0/en unknown
-
2015
- 2015-01-19 TN TNP2015000029A patent/TN2015000029A1/fr unknown
- 2015-02-03 CL CL2015000256A patent/CL2015000256A1/es unknown
- 2015-02-05 SA SA515360007A patent/SA515360007B1/ar unknown
- 2015-02-10 PH PH12015500294A patent/PH12015500294A1/en unknown
- 2015-03-09 EC ECIEPI20158851A patent/ECSP15008851A/es unknown
- 2015-10-16 US US14/884,826 patent/US20160031872A1/en not_active Abandoned
- 2015-11-06 HK HK15110950.0A patent/HK1210161A1/xx not_active IP Right Cessation
-
2017
- 2017-07-27 US US15/661,644 patent/US20170320867A1/en not_active Abandoned
- 2017-11-16 US US15/814,927 patent/US10138229B2/en active Active
-
2018
- 2018-10-15 US US16/160,048 patent/US10875852B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2015000029A1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
PH12015502814A1 (en) | 4-membered ring carboxamides used as nematicides | |
PE20160995A1 (es) | Inhibidores de syk | |
PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
MX2016010571A (es) | Pirazolil-ureas como inhibidores de quinasas. | |
PH12016501633B1 (en) | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
PH12014502169A1 (en) | N-cyclylamides as nematicides | |
MX2015001207A (es) | Compuestos de heteroarilo y heterociclo novedosos, composición y métodos de los mismos. | |
MX355943B (es) | Carboxamidas primarias como inhibidores de btk. | |
GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
WO2013083859A3 (fr) | Composés substitués de n-(tétrazol-5-yl)- et n-(triazol-5-yl) arylcarboxamides et leur utilisation comme herbicides | |
MY182082A (en) | Biheteroaryl compounds and uses thereof | |
MD4521C1 (ro) | Compuşi antivirali pe bază de imidazolil-dihidroizocromeno-naftoimidazoli condensaţi | |
MX340756B (es) | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. | |
PH12014502333A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
PH12016501071B1 (en) | Serine/threonine kinase inhibitors | |
WO2013072528A3 (fr) | Composés de n-(tétrazol-5-yl)- et n-(triazol-5-yl)pyridin-3-yl-carboxamides substitués et leur utilisation en tant qu'herbicides | |
MX2015013419A (es) | Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa. | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
MX349548B (es) | Compuestos de tienopirimidina. | |
PH12018500151A1 (en) | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof | |
MX2016001641A (es) | Ciclobutilcarboxamidas como nematicidas. |